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Abstract
Background: The burden of cardiovascular disease (CVD) and CVD risk conditions is rapidly increasing in low- and
middle-income countries, where health systems are generally ill-equipped to manage chronic disease. Policy makers
need an understanding of the magnitude and drivers of the costs of cardiovascular disease related conditions to
make decisions on how to allocate limited health resources.
Methods: We undertook a systematic review of the published literature on provider-incurred costs of treatment for
cardiovascular diseases and risk conditions in low- and middle-income countries. Total costs of treatment were
inflated to 2012 US dollars for comparability across geographic settings and time periods.
Results: This systematic review identified 60 articles and 143 unit costs for the following conditions: ischemic heart
disease, non-ischemic heart diseases, stroke, heart failure, hypertension, diabetes, and chronic kidney disease. Cost
data were most readily available in middle-income countries, especially China, India, Brazil, and South Africa. The
most common conditions with cost studies were acute ischemic heart disease, type 2 diabetes mellitus, stroke,
and hypertension.
Conclusions: Emerging economies are currently providing a base of cost evidence for NCD treatment that may
prove useful to policy-makers in low-income countries. Initial steps to publicly finance disease interventions should
take account of costs. The gaps and limitations in the current literature include a lack of standardized reporting as
well as sparse evidence from low-income countries.
Keywords: Cardiovascular disease, CVD, Systematic review, Economic evaluation, Non-communicable disease, Cost
analysis
Background
Cardiovascular disease (CVD) and CVD risk conditions,
such as hypertension, type 2 diabetes mellitus (T2DM),
and chronic kidney disease (CKD), are the leading cause
of global morbidity and mortality [1]. Increasingly larger
proportions of the global population are exposed to risk of
non-communicable disease (NCD), such as urbanization,
tobacco use, and sedentary behavior [2]. The growing
prevalence of these conditions is particularly troublesome
in low- and middle-income countries (LMICs), where age-
specific rates for NCD mortality are nearly twice as high
as in high-income countries [3], and treatment can be very
costly [4]. There is evidence that health systems in these
settings are already strained by the dual burden of infec-
tious and chronic disease, especially in resource-limited
settings [5]. Many people suffering from CVD in LMICs
remain untreated, or their conditions are poorly man-
aged, due to lack of access to primary health care and
high costs [6].
Efforts to improve prevention and management of
NCDs in LMICs are increasing. Mortality reduction
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targets, such as the World Heart Federation’s 25 × 25
and the Lancet’s 40 × 30, are unprecedented in putting
NCDs on the international agenda [7, 8]. The resources
required in order to meet these targets in any given LMIC
are less clear. Economic evaluations are especially import-
ant for settings that do not yet have policies or the infra-
structure in place to address these emerging issues [9].
Unfortunately, financial and economic cost estimates of
these interventions in LMICs are limited. In order to raise
awareness of the economic costs of CVD and to support
increased allocation of resources for addressing CVD and
risk conditions, accurate cost data are needed by donors,
ministries of health and economic modelers.
Recent reviews of household burden or cost-
effectiveness of CVD interventions in LMICs have
been published [6, 10–13]; however, there are no re-
cent reviews, to our knowledge, of provider-incurred
costs of interventions for CVD and risk conditions.
We therefore reviewed literature on the provider-
incurred costs for the treatment of cardiovascular and
related risk conditions in health system settings of
LMICs. Specifically, we consider diabetes, chronic
kidney disease, hypertension and hyperlipidemia,
stroke, ischemic heart disease, and non-ischemic heart
diseases. We chose these conditions because of their
interrelated risk factors and the large overlap in clin-
ical resources that are required to management them.
We will refer to the entire grouping as “CVRD” (car-
diovascular and related diseases) throughout the re-
mainder of the paper.
Our primary objective was to present the level and
variability in direct medical or programmatic costs for
treating CVRD in LMICs. Our secondary objective was
to identify gaps in knowledge and suggest future eco-
nomic research needs to support policy development, re-
source allocation, and decision-making.
Methods
Search strategy and article retrieval
We conducted our review according to the PRISMA
guidelines [14]. We searched the following databases:
Medline, EMBASE, NHS-EED, HEED and EconLit. We
adapted the search terms specifically to each database,
using 1) terms related to cardiovascular diseases and risk
conditions plus 2) terms for LMICs and regions plus 3)
terms denoting economic evaluation. Additional file 1
details the full strategy. We limited our results to articles
published on or after January 1st, 2000 until approxi-
mately July 1st, 2014. We screened eligible titles and
abstracts to determine which articles would be included
for final review. Two independent reviewers reviewed
the full text articles. In addition, we examined the
references of the included articles and prior reviews for
potentially relevant studies. Broadly, the following cri-
teria were used to determine inclusion:
 Included an economic evaluation
 Included evaluation of at least one low- or middle-
income country (as defined by the World Bank)
 Referred to our previously standardized list of
cardiovascular or related-related conditions
 Made available in English
 Published on or after January 2000.
We used both the Drummond Checklist and Mogyorosy
and Smith’s 2012 literature review for guidance in creating
the following guidelines regarding quality and inclusion
[15, 16]:
 The study must have conducted at least one type of
economic evaluation, including cost analysis, cost-
effective analysis, or cost-utility analysis, with clearly
presented unit cost data.
 We did not consider costs with health outcomes as
a denominator, such as disability-adjusted life years
(DALYs), quality adjusted life years (QALYs), or life-
years saved (LYS).
 The study must have utilized either original unit
cost data regarding a CVRD intervention delivered
in a health systems setting, or unit costs from a
credible and known source, such as WHO-
CHOICE. We did not consider population-level
interventions or policy costs.
 The study must have presented direct intervention
costs (medical or programmatic) from the provider
perspective, regardless of payer or indirect costs.
Studies that considered multiple perspectives were
only considered if they clearly delineated provider
costs. Provider costs were defined as those
delivering the services, such as those incurred by
health systems, hospitals or clinics, governmental
bodies, funders, or programs.
 The study had to meet certain quality standards,
which includes having a description of the
intervention and analysis, detailing the time and
location of data collection, and clearly stating the
year and currency of presented costs.
To inform the organization and synthesis of the
literature across conditions and interventions, we cre-
ated a conceptual framework of the clinical and pub-
lic health considerations in CVD treatment (Fig. 1).
There are several points at which one can intervene
on cardiovascular risk factors, risk conditions, and
CVDs themselves, both within and outside of the
health system. This review examines only the costs
that exist within the health sector, and health facilities
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specifically, but across the spectrum of cardiovascular
risk conditions and diseases themselves.
Data extraction
For each eligible study we entered the following infor-
mation into an electronic database: condition(s), country
or region, target population, type of treatment or inter-
vention, and level of care. We also noted study methods,
such as sample size and strategy, exchange rate, discount
rate, sensitivity analysis, and cost categories. The total
treatment or intervention costs, defined as the total cost
per patient, were extracted in their original currency and
year. For acute events, we used the total cost per patient
as presented. For recurring costs, such as hemodialysis
treatments or ongoing hypertension management, we
calculated the cost per treatment or per year. Differences
in inpatient and outpatient costs were noted where
reported and applicable. Of note, most of the included
studies reported multiple costs, particularly if they dis-
cussed more than one CVRD intervention or more than
one geographic setting.
We converted all costs to US Dollars (2012), the cur-
rency and year in which we present all costs in this
paper. When possible, we extracted the data in local cur-
rency units (LCUs), inflated it to 2012 rates using the
World Bank consumer price indices, and converted it to
2012 US Dollars via World Bank rates. When costs were
presented for regions, we used the largest LMIC country in
the region as a proxy. For data presented in international
dollars, we converted it back into LCUs using World Bank
Purchasing Power Parity, then we followed our standard
processes. Once the data were in a common currency, we
grouped similar interventions and qualitatively compared
the magnitudes and variability of total and input costs. We
combined data into the two overarching groups to reflect
our aforementioned framework: management of CVD risk
conditions and treatment of acute and chronic CVDs. The
former group included hypertension, hyperlipidemia, CKD,
T2DM, and generic CVD prevention. The latter group
focused specifically on ischemic heart disease, non-
ischemic heart diseases, stroke, heart failure, T2DM
sequelae (specifically, microvascular complications such
as foot ulcers and retinopathy), and end-stage renal
disease (ESRD), which is due predominately to poorly
controlled hypertension and T2DM.
Results
The results of the systematic search process can be
found in Fig. 2. 60 studies met our final inclusion cri-
teria, presenting approximately 143 unit costs reported
in Table 1. An additional 121 studies were reviewed at
the full text stage but were excluded on the basis of our
inclusion criteria or for methodological reasons, i.e., they
did not meet the criteria in our quality checklist.
The number of published articles for CVD costs in
LMICs has increased dramatically since 2000, as seen in
Fig. 3. In fact, we identified only five articles in the years
2000–2006, increasing to 16 articles published in 2013,
Fig. 1 CVRD Conceptual Framework. This framework informed our inclusion criteria and subsequent data extraction and organization
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the last complete year of our review. Most of the cost
data occurred either in urban areas or at the national
level of middle income countries, with only four studies
considering low-income countries. The sample is mainly
from Asian countries (34 articles), dominated by studies
from India (8 articles) and China (12 articles). Almost a
quarter of the cost data came from China; India contrib-
uted the next highest frequency of cost data (14 %).
One-third of our cost data concerned diabetes, which
was a considerably higher proportion than any other
condition, and two-thirds of those diabetes costs were
from Asian-based studies.
We obtained cost data from a variety of economic
evaluations. Almost two-thirds of the articles (n = 37)
were cost analyses, meaning they only collected and
presented data on costs, not health outcomes. Thirty
studies determined the total costs of interventions by
reviewing hospital records while 29 studies used an in-
gredients approach, taking the sum cost of activities and
resources used to find the total costs. Only one study
used a questionnaire to collect data. Of the 60 stud-
ies, over half converted their costs in US Dollars or
the hypothetical currency “International Dollars” for
presentation (32 articles). Although it is difficult to
measure the quality of a study objectively, economic
evaluation guidelines recommend discounting future
costs and conducting sensitivity analyses when as-
sumptions are made. We noted that approximately
one-third of the 60 studies conducted sensitivity ana-
lysis, and one-fourth used discounting in their
methods; 11 articles used both.
Management of cardiovascular risk conditions
Our review identified 60 cost estimates from 31 articles
for clinical management of CVD risk conditions such as
hypertension, hyperlipidemia, chronic kidney disease
and T2DM). There were also brief mentions of pharma-
cological tobacco cessation measures, rheumatic fever
and generic CVD prevention strategies such as polypill
use. More than three-quarters of this data came from
Asian countries, and more than half from China, India
or Thailand.
We found 14 unit costs for hypertension management
in LMICs, with drug therapy ranging from $2.21–$76.29.
Using general practitioners in community programs cost
only $0.81–$8.67 per patient per year, compared to annual
outpatient costs to manage hypertension, which ranged
from $38.00 to $565.54 per patient. Only three studies
mentioned the costs of managing dyslipidemia, which
were similar to managing hypertension. One study looked
Fig. 2 Article Selection Flow Chart (PRISMA STANDARDS). Flow diagram for the selection of published articles evaluating the costs of providing
preventive care or treatment for cardiovascular disease, diabetes, and chronic kidney disease in low- and middle-income countries
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Table 1 Unit cost data for the treatment of cardiovascular risk conditions (USD 2012)
Sub-Condition
(If Applicable)







Management of cardiovascular risk conditions
Hypertension




Pharmacological high blood pressure and
cholesterol treatment [35]
Tanzania 1.57–54.28 Per year US (2005) $2.21–$76.29 Per patient
per year
Pharmacological high blood pressure
treatment [33]
Argentina 49.72 Per patient
per year
US (2007) $52.24 Per patient
per year
Community Hypertension Control Program:
Home Health Education and General
Practitioner [36]
Pakistan 3.99 Per patient
per year
US (2007) $4.96 Per patient
per year
Community Hypertension Control Program:
Home Health Education [36]
Pakistan 3.34 Per patient
per year
US (2007) $4.15 Per patient
per year
Community Hypertension Control Program:
General Practitioner [36]
Pakistan 0.65 Per patient
per year




China 7.17 Per patient
per year
US (2009) $8.67 Per patient
per year
Guideline-Oriented Training Program for
Hypertension Control in Community
Health Centers [38]
China 79.30 Per year US (2002) $138.96 Per year




US (2001) $169.28 Per patient
per year
Hypertension Outpatient Treatment [39] China 487.30 Per patient
per year
US (2010) $565.54 Per patient
per year
Hypertension Outpatient Treatment at
Urban Health Clinic [40]














Hypertension Outpatient Treatment and
Medications [42]
Tanzania 38.00 Per patient
per year
US (2012) $38.00 Per patient
per year








Hypertensive Emergency Treatment Cost
(Inpatient and Outpatient) [43]
Congo,
Rep.




Screening for dyslipidemia among healthy
35–39 year olds [44]






Screening for dyslipidemia among healthy
35–60 year olds [45]








Argentina 118.79 Per patient
per year
US (2007) $124.81 Per patient
per year





Therapy for Patients with Diabetes,
Hypertension, and Nephropathy) [29]
China 2,013.00 Per year US (2004) $3,356.78 Per patient
per year
Irbesartan (Anti-hypertensive Drug Therapy
for Patients with Diabetes, Hypertension,
and Nephropathy) [29]
China 1,660.00 Per year US (2004) $2,768.13 Per patient
per year
Malaysia 332.00 Per year US (2004) $503.07
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Table 1 Unit cost data for the treatment of cardiovascular risk conditions (USD 2012) (Continued)
Amlodipine (Anti-hypertensive Drug Therapy




Irbesartan (Anti-hypertensive Drug Therapy
for Patients with Diabetes, Hypertension,
and Nephropathy) [29]
Malaysia 258.00 Per year US (2004) $390.94 Per patient
per year
Amlodipine (Anti-hypertensive Drug Therapy
for Patients with Diabetes, Hypertension, and
Nephropathy) [29]
Thailand 779.00 Per year US (2004) $1,302.06 Per patient
per year
Irbesartan (Anti-hypertensive Drug Therapy
for Patients with Diabetes, Hypertension,
and Nephropathy) [29]
Thailand 1,340.00 Per year US (2004) $2,239.75 Per patient
per year
Type 2 Diabetes Mellitus
Screening using fasting capillary blood
glucose [46]
China 10.00 Per test China
(2009)
$1.77 Per patient
Screening using Diabetes Risk Score [46] China 5.00 Per test China
(2009)
$0.89 Per patient
Screening for diabetes in a community
health clinic [47]
China 3.00 Per patient US (2007) $4.25 Per patient
Tertiary Hospital Diagnostic Test [46] China 95.00 Per test China
(2009)
$16.82 Per patient
Primary Care - Behavior management
program to prevent diabetes [48]
India 54.67 Per patient
per year
US (2006) $78.93 Per patient
per year
Primary Care - Metformin regimen to
prevent diabetes [48]
India 53.00 Per patient
per year
US (2006) $76.53 Per patient
per year
Primary Care - Behavior management
program with Metformin regime to
prevent diabetes [48]
India 69.67 Per patient
per year
US (2006) $100.59 Per patient
per year
Mean total annual direct medical cost
(without complication) [49]




Mean total annual direct medical cost
(with complication) [49]




Annual treatment costs (inpatient and
outpatient costs) [50]






Annual treatment costs (inpatient and
outpatient costs) [51]






Annual Diabetes Treatment in Community
Clinic (Including Inpatient and
Outpatient Visits) [52]
Brazil 1,319.15 Per year US (2010) $1,335.52 Per patient
per year
Annual treatment costs (inpatient and
outpatient costs) [53]
India 3,006.00 Per patient
per year
India (2012) $56.25 Per patient
per year
Urban Health Center providing primary
community care [40]







Inpatient stay w/o hypertension












India (2007) $629.18 Per
inpatient
stay
Inpatient stay w/o hypertension
(Average 7 Days LOS) [54]
India 28,000.00 Per two
years
India (2007) $419.45 Per patient
per year
Inpatient Stay w/hypertension
(Average 5 Days LOS) [54]
India 38,000.00 Per two
years
India (2007) $569.25 Per patient
per year
Inpatient Treatment: without complication
(Average 9.8 Days LOS) [55]
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at the costs of managing chronic kidney disease across
China, Malaysia and Thailand, with China being more
expensive than Malaysia by a scale of six to eight. We
identified 30 unit costs for managing diabetes. Two stud-
ies produced four costs on diagnosing diabetes, the most
expensive of which were based in tertiary hospitals. Seven
studies presented ten annual per patient costs of man-
aging diabetes in a clinical setting, which ranged from
$56.25 in India to $2,479.82 in China; the costs were
higher in cases with complications and sequelae. Nine
studies also presented 16 costs on inpatient and outpatient
treatment for diabetes. Inpatient stays per bed-day ranged
from $59.92–$143.14 with an average length of stay of
around 7 days. An outpatient visit ranged from
$4.63–$34.28, and we also found a ten-fold variation in
yearly outpatient costs.
Treatment and management of acute and chronic
cardiovascular conditions
Our review also identified 83 cost estimates from 34
studies regarding the treatment of ischemic heart disease
Table 1 Unit cost data for the treatment of cardiovascular risk conditions (USD 2012) (Continued)
Inpatient Treatment: with chronic
complications (Average 9.8 Days LOS) [55]





Inpatient/Hospital Admission [56] Thailand 95.99 Per day US (2008) $112.65 Per day
Inpatient Treatment in Community Clinic
(No LOS Stated) [52]
Brazil 26.32 Per year US (2010) $26.65 Per patient
per year
Outpatient Care [56] Thailand 3.94 Per
outpatient
visit
US (2008) $4.63 Per
outpatient
visit
Outpatient Care in Community Clinic [52] Brazil 1,216.33 Per year US (2010) $1,231.43 Per patient
per year
Outpatient treatment for patient without
complications [57]
India 4,493.00 Per year India (2009) $112.05 Per
inpatient
stay
Outpatient Treatment [58] Nepal 16.95 Per
outpatient
visit
US (2010) $17.45 Per
outpatient
visit
Outpatient Treatment [58] Nepal 130.52 Per year US (2010) $134.38 Per patient
per year
Outpatient Treatment [59] Brazil 1,014.00 Per patient
per year
US (2007) $1,322.64 Per patient
per year




















Modified poly-pill strategy [33] Argentina 103.46 Per patient
per year
US (2007) $108.70 Per patient
per year








Bupropion treatment HCW counseling
for tobacco cessation [33]
Argentina 117.15 Per patient
per year




Prevention of Rheumatic Fever (throat
culture)
India 1,088.56 Per patient India (2007) $32.61 Per patient
Post rheumatic fever prophylaxis [61] India 879.35 Per patient India (2007) $26.35 Per patient




2,958.00 Per patient US (2010) $2,927.41 Per patient
Echocardiographic screening for rheumatic
heart disease in schoolchildren [63]
Fiji 2.07 Per patient
screened
US (2008) $2.27 Per patient
screened
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(IHD), stroke, heart failure, non-ischemic heart diseases,
T2DM sequelae, and end-stage renal disease (ESRD).
Treatment of IHD typically consists of diagnostic pro-
cedures, surgical or other advanced medical procedures,
and post-operative and long-term outpatient care. We
found 8 articles analyzing IHD treatment with a total of
18 unit costs. An inpatient visit averaged $8,800, with a
range from $455 to $22,500. The highest inpatient costs
were associated with longer hospitalization periods,
more severe conditions, and surgical interventions. The
costs of surgical procedures, including catheter-based
procedures (stenting and angioplasty) or coronary artery
bypass surgery (CABG), ranged from $4,000–$22,000
per patient per procedure depending on the diagnostics,
the complexity of the procedure, and whether medical
therapy and recovery costs were included in the total
cost estimates.
Our search returned 15 articles and 24 unit costs for
both ischemic stroke (IS) and hemorrhagic stroke (HS),
though many studies did not specify the type of stroke.
In most settings, IS is the more common of the two, is
generally easier to treat, and has a lower case-fatality
rate. Four articles compared the costs HS and IS
treatment [17–20]. Hemorrhagic strokes were generally
more severe, required longer hospital stays, and involved
surgical or intensive care unit costs; HS treatment costs
were between 0 % and 50 % higher than IS treatment.
The majority of articles provided the inpatient cost per
stroke event, but did not distinguish the type of strokes.
The average inpatient cost of a stroke was $3,240, but
this varied widely by geographic setting, technical
resources used, and average length of stay.
Five studies reported costs of T2DM sequelae, namely,
diabetic foot ulcers and retinopathy. Severity of these
impairments and costs saved by screening drove the
total costs of both, though in opposite directions
[21–25]. For instance, screening for retinopathy was
generally below $30, while diabetic foot ulcers ranged
from less than $1 to over $7,000 in the cases of
infection and amputation.
Five studies reported costs of end-stage renal disease
(ESRD), primarily long-term dialysis or renal transplant-
ation. The cost of one session of hemodialysis for ESRD
ranged $79 to $97 [26–28], while one study estimated
average annual dialysis costs at $61,000 in Southeast
Asia [29]. Kidney transplantation and post-operative care
Fig. 3 Articles Published by Year & Region. Figure shows the number of articles identified by our study disaggregated by the year in which they
were published and the region (as defined by the World Bank) for which they provide data. Studies providing data for more than one region
were categorized as “multiple”
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Table 2 Unit cost data for the treatment of cardiovascular disease and related condition (USD 2012)
Treatment and Management of Acute/Chronic Cardiovascular and Related Conditions
Ischemic Heart Disease












11,431.00 Per patient US
(2001)
$22,500.46 Per patient
CABG Procedure (Procedure only, no
medical therapy) [64]
China 7,300.00 Per patient US
(2007)
$10,339.01 Per patient
CABG Procedure (Procedure and Medical
Therapy) [65]
Armenia 3,368.19 Per patient US
(2005)
$5,546.46 Per patient
CABG Procedure (Procedure and Medical
Therapy) [66]
India 8,055.00 Per patient US
(2006)
$11,630.62 Per patient
Stenting Procedure (Procedure only, no
medical therapy) [64]







4,737.00 Per patient US
(2001)
$9,324.18 Per patient
Total operative procedures and examinations
[67]
Brazil 444.29 Per patient Brazil
(2001)
$455.47 Per patient
Coronary Angioplasty Diagnostic Strategy
Including Therapy [64]
China 3,568.00 Per patient US
(2007)
$5,053.37 Per patient
Computed Tomography Angiography and
Coronary Angioplasty Diagnostic Strategy [64]
China 2,971.00 Per patient US
(2007)
$4,207.84 Per patient
Inpatient Visit (All direct medical costs) [33] Argentina 4,245.39 Per patient US
(2007)
$4,460.54 Per patient




















5,636.00 Per patient US
(2001)
$11,093.74 Per patient
Additional cost if a CABG or valve
replacement surgery results in a hospital-
acquired infection [66]
India 14,818.00 Per patient US
(2006)
$21,395.72 Per patient
Post CHD with CABG (1st year) [32] South
Africa




Post CHD with CABG (subsequent years) [32] South
Africa




Post CHD without CABG (1st year) [32] South
Africa















Inpatient Visit for Stroke Care (Average 11.8
Days LOS) [17]
Turkey 1,348.00 Per patient US
(2007)
$1,444.46 Per patient
Inpatient Visit for Stroke Care (Average 12
Days LOS) [18]
Brazil 1,831.00 Per patient US
(2007)
$2,388.33 Per patient
Tertiary Treatment and Follow-Up - Coiling
(6 months) [69]
Pakistan 304,800.00 Per patient Pakistan
(2007)
$6,236.79 Per patient
Tertiary Treatment and Follow-Up -
Endovascular clipping (6 months) [69]





Inpatient Visit for Stroke Care (Average 10.4
Days LOS) [17]
Turkey 956.00 Per patient US
(2007)
$1,024.41 Per patient
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Table 2 Unit cost data for the treatment of cardiovascular disease and related condition (USD 2012) (Continued)
Inpatient Visit for Stroke Care (Average 13.3
Days LOS) [18]
Brazil 1,645.00 Per patient US
(2007)
$2,145.71 Per patient
Inpatient Visit for Stroke Care (Average 18.5
Days LOS) [70]





Inpatient Visit for Stroke Care (Average 18.5
Days LOS) [70]
China 983.00 Per patient US
(2010)
$1,140.84 Per patient
Diagnostics and preventative care for
high-risk patients at a tertiary hospital [71]
















Direct Medical Costs for Managing a Stroke
Patient in Year Following Stroke [72]
Nigeria 62,217.00 Per patient US
(2012)
$62,217.00 Per patient
Direct Medical and follow up (6-months) [73] India 57,381.00 Per patient India
(2011)
$1,173.80 Per patient
Inpatient Visit for Stroke Care: Average
across all wards (3–5 Days Ave. LOS) [31]
Pakistan 1,179.00 Per patient US
(2001)
$2,160.99 Per patient
Inpatient Visit for Stroke Care: ICU
(3–5 Days LOS) [31]
Pakistan 3,583.50 Per patient US
(2001)
$6,568.20 Per patient
Inpatient Visit for Stroke Care: Private Ward
(3–5 Days LOS) [31]
Pakistan 1,248.00 Per patient US
(2001)
$2,287.46 Per patient
Inpatient Visit for Stroke Care: General Ward
(3–5 Days LOS) [31]
Pakistan 1,010.00 Per patient US
(2001)
$1,851.23 Per patient
Inpatient Visit for Stroke Care
(LOS not stated) [32]
South
Africa
8,633.00 Per patient US
(2001)
$16,992.95 Per patient
Inpatient Visit for Stroke Care
(LOS not stated) [74]
Tanzania 138,000.00 Per patient Tanzania
(2006)
$160.18 Per patient
Inpatient Visit for Stroke Care
(LOS not stated) [33]
Argentina 3,455.48 Per patient US
(2007)
$3,630.60 Per patient
Inpatient Visit for Stroke Care
(Up to 3 Days LOS) [43]
Congo,
Rep.




Inpatient Visit for Stroke Care








Inpatient Visit for Stroke Care: small








Inpatient Visit for Stroke Care: tertiary








Inpatient Visit for Stroke Care









Inpatient treatment for heart failure due
to systolic or diastolic dysfunction with a
Chagas’ cardiomyopathy diagnosis [75]
Brazil 467.00 Per day Brazil
(2006)
$324.23 Per day












Inpatient treatment for heart failure due to
systolic or diastolic dysfunction with
Non-Chagas’ cardiomyopathy
(other etiologies) [75]
Brazil 308.00 Per day Brazil
(2006)
$213.84 Per day
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Table 2 Unit cost data for the treatment of cardiovascular disease and related condition (USD 2012) (Continued)
Inpatient Care (Up to 3 Days LOS) [43] Congo,
Rep.














Operations and treatments, including pre
and post-operative care [67]









1,597.00 Per patient US
(2010)
$1,580.49 Per patient
Tertiary care (including inpatient care and
surgery) [61]
India 1,547.17 Per patient India
(2007)
$46.35 Per patient
Type Two Diabetes Mellitus
Diabetic Foot
Ulcers
Total treatment [21] Pakistan 2,700.00 Per patient Pakistan
(2005)
64.15–$1165.65 Per patient
Total Treatment (healed) [22] China 1,673.00 Per patient $Int
(2010)
$585.60 Per patient
Total Treatment (trans-tibial amputation) [22] China 21,372.00 Per patient $Int
(2010)
$7,480.87 Per patient
Total Treatment (healed) [22] India 1,192.00 Per patient $Int
(2010)
$85.51 Per patient
Total Treatment (trans-tibial amputation) [22] India 19,599.00 Per patient $Int
(2010)
$1,405.97 Per patient
Total Treatment (healed) [22] Tanzania 102.00 Per patient $Int
(2010)
$0.24 Per patient
Total Treatment (trans-tibial amputation) [22] Tanzania 3,060.00 Per patient $Int
(2010)
$7.30 Per patient
Total Treatment [23] Nigeria 93,256.70 Per patient Nigeria
(2003)
$1,618.55 Per patient




22.00 Per patient US
(2007)
$26.10 Per patient




144.00 Per patient US
(2007)
$170.85 Per patient
Screening Retinal examination at a hospital
[25]
India 5.84 Per patient US
(2009)
$7.05 Per patient
Screening single laser photocoagulation
treatment at a hospital [25]
India 7.51 Per patient US
(2009)
$9.07 Per patient
Screening Using Telescreening in rural areas
[25]
















1 session of hemodialysis in a hospital [27] Jordan 72.00 Per session US
(2010)
$78.76 Per session





52.60 Per session US
(2007)
$96.66 Per session
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ran from $5,000 to $21,000 in the Sudan and Iran, re-
spectively [28, 30].
Other types of CVD, such as heart failure, Chagas
cardiomyopathy (CC), congenital heart disease, and
rheumatic heart disease, are important contributors to
the burden of NCDs in LMICs. However, we identified
only a handful of studies on the cost of treating these
conditions (Table 2).
Discussion
Treating CVD and its risk conditions is complex, due in
part to the interrelationship between hypertension,
diabetes, and ischemic heart disease, and the fact that
multiple shared risk factors affect CVD health outcomes.
The clinical heterogeneity of CVD can make treatment
costs for a single condition much more variable than in
the case of infectious diseases or some other chronic
diseases; these factors also affect the mean and distribu-
tion of costs within and across similar conditions. For
instance, CVD encompasses different types of heart and
related diseases, such as hypertension, stroke, and heart
failure, with different levels of severity, and associated
care and management. There are numerous clinical
protocols for treating complicated conditions, and treat-
ment includes different combinations of drugs, diagnos-
tics and imaging technologies, surgery and different
requirements for inpatient care and follow-up visits,
making comparisons between studies all but impossible.
Additionally, there are large variations in clinical char-
acteristics, capabilities, and practices among and within
countries; it is possible to have a wide distribution of
costs even within a hospital if they offer various levels
of care, such as general, specialty, and intensive care
wards [31].
Another factor affecting the variation in costs was
differences in methodology used across studies. There
was a lack of standard reporting across the studies, most
notably failure to describe cost ingredients. When stud-
ies disaggregated costs, there were not clear and com-
mon categories for input or activity cost categories. In
addition, for disaggregated input costs, it was unclear
when activities included personnel in the costs. Many
studies provided costs for imaging, diagnostic or thera-
peutic services, without indicating whether personnel
costs were included. Surgery was a common category,
but descriptions of what resources comprised surgery or
surgical procedures were absent from the majority of the
studies. Cost data was most informative when disaggre-
gated into categories and inputs, allowing the reader to
better understand heterogeneity and make more useful
comparisons. We also noticed a lack of clinical protocol
reporting in publications. Reporting on clinical protocols
Table 2 Unit cost data for the treatment of cardiovascular disease and related condition (USD 2012) (Continued)










Maintenance post index year of transplant
patient [29]








Maintenance post index year of transplant
patient [29]








Maintenance post index year of transplant
patient [29]




Kidney transplantation, including operation
and following year [28]
Sudan 34,097.85 Per patient Sudan
(2009)
$18,131.93 Per patient
Kidney transplantation, after the first year [28] Sudan 24,499.00 Per patient Sudan
(2009)
$13,027.63 Per patient
Transplantation Procedure [30] Iran,
Islamic
Rep.
2,048.00 Per patient US
(2005)
$4,769.20 Per patient
Total cost (Transplant procedure, 1 year




9,224.00 Per patient US
(2005)
$21,480.05 Per patient
Definitions: Per capita costs were divided by the population of the study country in 2012 as defined by the World Bank. Primary prevention defined as actions to
reduce the probability of initial occurrence of disease. Secondary prevention defined as actions following the occurrence of disease to prevent either the
recurrence of the same event or to reduce the risk of a different but related event
Abbreviations: CABG Coronary Artery Bypass Grafting, CHD Coronary Heart Disease, LOS Length of Stay, ICU Intensive Care Unit
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underlying the CVD interventions may help readers
evaluate the comparability and transferability of costs es-
timates across studies, depending on the study objective.
Trends in the data emerged despite these limitations.
It is clear that there is growing interest and concern
about the prevalence and cost of treating cardiovascular
and risk conditions at every national income level.
BRICS countries and a few other populous Asian coun-
tries produced about three-quarters of the literature we
identified, laying a foundation of evidence for the costs
of treating CVRDs in LMICs. The current evidence
confirms that is expensive to provide treatment for com-
plicated or advanced cardiovascular conditions, with
inpatient treatment for CVD easily costing upwards of
$10,000 per patient (Fig. 4). Looking at the distribution
of costs by condition, managing risk conditions is gener-
ally much less expensive than treating acute CVD condi-
tions (Fig. 5).
Our review identified critical gaps in information and
demonstrated the substantial heterogeneity in treatment
costs for CVRD across the available data for LMIC
countries. The most obvious gap was the need for more
consistent methodology, with clear presentation of data
on cost ingredients and drivers. Cost data are used to
inform resource allocation and to improve efficiency;
health policy makers thus need to understand the under-
lying causes of health expenditures in order to make
informed decisions. We identified no longitudinal stud-
ies in LMICs, however several modeled studies looked at
health costs over a longer period of time. We anticipate
that longitudinal studies would be particularly revealing
regarding costs of chronic conditions, such as hyperten-
sion and diabetes, which require lifelong management.
In the absence of longitudinal studies, health decision-
makers are currently allocating CVD resources with an
incomplete picture of future costs.
We found very few cost analyses of CVD conditions
conducted in low-income countries. While these coun-
tries are likely the most heavily resource-constrained,
they are also likely the least prepared to prevent and
treat CVD conditions. We found no data on the cost of
diabetes care in low-income countries. Middle-income
countries, particularly upper-middle income countries
such as Brazil, China, and South Africa, have produced
research or publications regarding technologically com-
plex interventions, revealing relatively higher health
system capacity. As the double-burden of infectious and
chronic conditions increases, and policy makers in low-
income countries expand health resources for chronic
conditions, published studies from other LMICs can
provide economic evidence on CVD interventions.
Because our analysis focused on the unit costs of
clinical interventions, we did not include many of the
WHO Best Buys for NCDs such as tobacco taxation
and regulation, population salt regulation, or health
and physical activity promotion. Population based pre-
vention measures typically cost pennies per person,
but the total cost to the government will depend on
the population size. It was beyond the scope of this
paper to compare the total costs of population based
interventions with clinical prevention and treatment
costs. The evidence in this review strongly suggests
Fig. 4 Hospital Costs by Condition (USD 2012). Showing the average, minimum, and maximum costs of inpatient treatment for various
cardiovascular and chronic kidney disease conditions. Source: extracted cost data for this review
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that costs quickly escalate with advanced CVRD treat-
ment; future investment in population prevention of
CVRDs could reduce the need for these expensive
clinical interventions.
We also excluded studies presenting the cost of
implementing guidelines for initiating prevention strat-
egies of CVRDs based on absolute risk [32, 33]. While
prevention is extremely important for averting prema-
ture death and the high costs of surgery and post-
operative care, setting risk guideline thresholds is less
associated with changes in unit costs than with changes
in long-term cost-effectiveness and total budget impact.
The economic evaluations we identified regarding risk
guidelines ultimately fell outside of our purview due to
their health outcome denominators.
Conclusion
The evidence for CVRD treatment and prevention
costs in LMICs is limited, particularly in low-income
countries. We recommend conducting economic stud-
ies alongside efforts to scale up treatment and pre-
ventions on CVRD in these settings. Initially standard
methods of care or clinical protocol could be used to
inform costs of CRVD treatment and prevention in
order to estimate costs and their key drivers are
across settings. There is also a need to estimate the
actual resource use and costs in the provision of care,
as such information can be used to improve efficiency
and budgeting over time. In addition to following rec-
ommended costing analysis protocols [15], future re-
search on the costs of CVD prevention and care
Fig. 5 Unit Cost Distributions. Figure of four overlapping histograms showing the distribution of identified costs per patient for four conditions:
hypertension management, diabetes mellitus, stroke, and acute ischemic heart disease. These four conditions had the most robust data available
in the review
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should disaggregate the cost inputs, especially long
term costs, since most individuals with CVRD experi-
ence worsening disease severity and more sequelae
over time.
The burden of CVRD in LMIC is already substantial
and will continue to increase in the absence of concerted
prevention efforts, which could contain costs by redu-
cing future spending on CVD. At the same time, the
prevalence of CVD is already very high in regions such
as Latin America and South and East Asia. Hence,
efforts to allocate NCD resources equitably will inevit-
ably include a balance of both prevention and advanced
treatments for existing cases of CVD. Ongoing efforts to
understand the cost of delivering CVRD care in these
regions will be critical to achieving universal health
coverage and improving overall population health.
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